Search research articles
Contact Us
Filters
Showing results (511-520 of 549) with videos related to
Page
of 55
Sort By:
Breast Cancer Research : BCR
|
February 14, 2025
HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials WSG-ADAPT-HR+/HER2-, WSG-PlanB, and WSG-ADAPT-TN
Gilda Schmidt, Oleg Gluz, Matthias Christgen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 3, 2020
A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER<sup>+</sup> HER2<sup>-</sup> Primary Breast Cancer
John F R Robertson, Abigail Evans, Stephan Henschen, et al.
Nature Communications
|
December 15, 2019
Obesity and disease severity magnify disturbed microbiome-immune interactions in asthma patients
David Michalovich, Noelia Rodriguez-Perez, Sylwia Smolinska, et al.
Elife
|
September 11, 2015
Geological and taphonomic context for the new hominin species Homo naledi from the Dinaledi Chamber, South Africa
Paul H G M Dirks, Lee R Berger, Eric M Roberts, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 9, 2025
Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study
Philippe L Bedard, Komal L Jhaveri, Melissa K Accordino, et al.
The Lancet. Oncology
|
May 3, 2025
Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial
Sherko Kuemmel, Monika Graeser, Peter Schmid, et al.
The New England Journal of Medicine
|
February 9, 2022
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
Peter Schmid, Javier Cortes, Rebecca Dent, et al.
Lancet (London, England)
|
April 6, 2024
3-year invasive disease-free survival with chemotherapy de-escalation using an <sup>18</sup>F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial
José Manuel Pérez-García, Javier Cortés, Manuel Ruiz-Borrego, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 17, 2019
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial
Peter Schmid, Jacinta Abraham, Stephen Chan, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 10, 2018
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1)
Marcin Kowanetz, Wei Zou, Scott N Gettinger, et al.
Page
of 55
Search research articles
Search
Showing results (511-520 of 549) with videos related to
Sort By:
Page
of 55
Breast Cancer Research : BCR
|
February 14, 2025
HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials WSG-ADAPT-HR+/HER2-, WSG-PlanB, and WSG-ADAPT-TN
Gilda Schmidt, Oleg Gluz, Matthias Christgen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 3, 2020
A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER<sup>+</sup> HER2<sup>-</sup> Primary Breast Cancer
John F R Robertson, Abigail Evans, Stephan Henschen, et al.
Nature Communications
|
December 15, 2019
Obesity and disease severity magnify disturbed microbiome-immune interactions in asthma patients
David Michalovich, Noelia Rodriguez-Perez, Sylwia Smolinska, et al.
Elife
|
September 11, 2015
Geological and taphonomic context for the new hominin species Homo naledi from the Dinaledi Chamber, South Africa
Paul H G M Dirks, Lee R Berger, Eric M Roberts, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 9, 2025
Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study
Philippe L Bedard, Komal L Jhaveri, Melissa K Accordino, et al.
The Lancet. Oncology
|
May 3, 2025
Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial
Sherko Kuemmel, Monika Graeser, Peter Schmid, et al.
The New England Journal of Medicine
|
February 9, 2022
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
Peter Schmid, Javier Cortes, Rebecca Dent, et al.
Lancet (London, England)
|
April 6, 2024
3-year invasive disease-free survival with chemotherapy de-escalation using an <sup>18</sup>F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial
José Manuel Pérez-García, Javier Cortés, Manuel Ruiz-Borrego, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 17, 2019
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial
Peter Schmid, Jacinta Abraham, Stephen Chan, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 10, 2018
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1)
Marcin Kowanetz, Wei Zou, Scott N Gettinger, et al.
Page
of 55